Weekly docetaxel (D) and irinotecan (I) in patients (pts) with recurrent or metastatic head and neck cancer (HNC): A phase II trial of the Eastern Cooperative Oncology Group (ECOG)

Argiris, Athanassios; Goldwasser, Meredith A.; Brockstein, B.; Axelrod, Rita; Forastiere, A.

doi:10.1200/jco.2005.23.16_suppl.5528

Cited by 9 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of phase II studies with combination cytotoxic regimens for the second-line treatment of recurrent/metastatic SCCHN have also reported MSTs inferior to that observed in the current study, including a MST of 4.5 months among 48 patients treated with vinorelbine, methotrexate, and bleomycin, 4 and a MST of 4.9 months among 35 patients treated with docetaxel and irinotecan. 7 The MST in the current study also compares favorably with that reported in the phase II study of cetuximab (Erbitux, ImClone Systems, Inc.; a monoclonal antibody targeting the epidermal growth factor receptor) that led to the Food and Drug Administration approval of cetuximab monotherapy for recurrent/ metastatic SCCHN after failure of platinum-based therapy. One hundred three patients with platinum-refractory recurrent/metastatic SCCHN were treated with single-agent cetuximab, with an objective response rate of 13%.…”

Section: Discussionsupporting

confidence: 77%

“…3 Data on the efficacy of chemotherapy in metastatic/recurrent SCCHN after failure of platinum-based therapy are limited, but response rates have been reported to range from 3% to 27%, with MST less than 6 months. [3][4][5][6][7] There is a great need for new and improved treatment options for this patient population, and current research efforts are focusing on molecularly targeted therapies.…”

mentioning

confidence: 99%

See 1 more Smart Citation

A Phase II Study of Lonafarnib (SCH66336) in Patients With Chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck

Hanrahan

Kies

Glisson

et al. 2009

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 77%

mentioning

confidence: 99%

A Phase II Study of Lonafarnib (SCH66336) in Patients With Chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck

Hanrahan

Kies

Glisson

et al. 2009

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…6 The outcome of previously treated patients is even worse because chemotherapy is generally ineffective in this setting, with response rates of less than 10% and median survival of about five months. 7 The identification of novel agents with activity in both previously untreated and pretreated patients is particularly warranted in incurable SCCHN.…”

Section: Introductionmentioning

confidence: 99%

A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer

Argiris

Cohen

Karrison

et al. 2006

Cancer Biology & Therapy

109

View full text Add to dashboard Cite

Background: Novel, effective therapies are warranted in the management of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Perifosine is an oral alkylphospholipid that inhibits AKT phosphorylation and has shown preclinical antitumor activity in head and neck cancer cell lines and xenografts.Patients And Methods: We conducted a phase II trial of perifosine in patients with incurable, recurrent or metastatic SCCHN. Previous therapy for recurrent or metastatic disease was limited to no more than one prior chemotherapy and one prior targeted/ biologic agent regimen. Patients had to have measurable disease, Eastern Cooperative Oncology Group performance status 0-2, and adequate laboratory parameters. Perifosine was given as a loading dose of 150 mg every 6 hours × 6 doses orally in the first two days, with antiemetic prophylaxis, followed by 100 mg/day orally without interruption. Administration via gastrostomy tube was allowed. Tumor response was assessed every two cycles (eight weeks). Biomarkers in pathways potentially affected by perifosine, including AKT, P-AKT, P38, p53 and p21 were measured on tumor tissue by immunohistochemistry by manual and automated methods.Results: Nineteen patients were enrolled. No objective responses were observed. One patient had stable disease as best response and 18 patients progressed at first evaluation. The median overall survival time was 5.5 months and the median progression-free survival time was 1.7 months. The most frequent toxicities were gastrointestinal (constipation, nausea, vomiting) and fatigue. One patient developed grade 4 anorexia. Although the sample size was small, a significant correlation was detected between high expression of P38 and AKT in baseline tumor tissue and better survival.Conclusions: Perifosine in the doses and schedule used lacks single-agent activity in SCCHN. Our data do not justify further investigation of perifosine as a single agent in SCCHN.

show abstract

“…Accrual is ongoing (15). Interest in irinotecan for the treatment of HNC patients has increased with the introduction of targeted agents.…”

Section: Discussionmentioning

confidence: 99%

Single Agent Irinotecan for the Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck (SCCHN)

Gilbert

Dang

Cmelak

et al. 2007

Clinical medicine. Oncology

View full text Add to dashboard Cite

show abstract

Weekly docetaxel (D) and irinotecan (I) in patients (pts) with recurrent or metastatic head and neck cancer (HNC): A phase II trial of the Eastern Cooperative Oncology Group (ECOG)

Cited by 9 publications

References 0 publications

A Phase II Study of Lonafarnib (SCH66336) in Patients With Chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck

A Phase II Study of Lonafarnib (SCH66336) in Patients With Chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck

A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer

Single Agent Irinotecan for the Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck (SCCHN)

Contact Info

Product

Resources

About